Important Safety Information
For topical dermatologic use only and not for ophthalmic or intravaginal use.
OXISTAT® (oxiconazole nitrate) Lotion is contraindicated in individuals who have shown hypersensitivity to any of its components. If a reaction suggesting sensitivity or chemical irritation should occur with the use of OXISTAT® Lotion, treatment should be discontinued and appropriate therapy instituted. If signs of epidermal irritation should occur, the drug should be discontinued.
In a clinical trial with OXISTAT® Lotion (N=269), the most common adverse events were burning and stinging (0.7% each) and pruritus, scaling, tingling, pain and dyshidrotic eczema (0.4% each).
Please see Full Prescribing Information for OXISTAT® Lotion.
You are encouraged to report negative side effects of prescription drugs to the FDA. Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Indication
OXISTAT® Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum.
The information on this site is intended for U.S. residents only.
OXISTAT® is a registered trademark of Fougera Pharmaceuticals, Inc.
© 2021 ANI Pharmaceuticals, Inc. All rights reserved.
Site Map
| Terms of Use |
Privacy Policy |
ANI Pharmaceuticals, Inc
The information on this site is intended for U.S. residents only.
10470 Rev 06/21
